We herein present a case of pediatric therapy-related myelodysplastic syndrome (t-MDS) with complex karyotype who was treated with azacitidine (AZA) for AML1-EVI1 fusion transcript as minimal residual disease after allogeneic hematopoietic stem cell transplantation (HSCT). The patient was started on AZA 41 days after the HSCT without having achieved complete remission. After 9 cycles of AZA, the AML1-EVI1 fusion transcript disappeared, and there was no manifestation of graft versus host disease during AZA treatment. Preemptive AZA treatment for minimal residual disease has an acceptable safety profile and appears to be an effective strategy for preventing or substantially delaying hematological relapse in pediatric patients with high-risk myelodysplastic syndrome after HSCT.
recent results of studies of low-dose AZA as maintenance or salvage therapy in higher-risk MDS and AML patients after allogeneic HSCT indicated that AZA is well tolerated and associated with a prolonged progression-free and overall survival. 4, 5 This report presents the case of a child with t-MDS who received AZA to treat and prevent disease recurrence after allogeneic HSCT.
CASE REPORT
An 11-year-old male was found to have a bleeding tendency. He had previously been diagnosed with medulloblastoma of the cerebellum at 1 year. After the gross total resection of the tumor, he had received chemotherapy for 6 months. The total doses of chemotherapy with cyclophosphamide, cisplatin, etoposide, vincristine, thiotepa, and melphalan were 12 g/m , 26 mg/kg, and 6 mg/kg, respectively. Furthermore, when he was 7 years old, he had been diagnosed with osteosarcoma of the right tibia. He had received chemotherapy for 1 year, and underwent gross total resection of the osteosarcoma. The total doses of chemotherapy using cisplatin, doxorubicin, methotrexate, ifosfamide, and pirarubicine during that period were 500 mg/m respectively. He had maintained a CR for both of cancers with subclinical cardiac dysfunction and cisplatin-induced hearing loss as a late effect. He was affected by 3 malignancies, but he had no family history of cancer which is associated with Li-Fraumeni syndrome. We have not checked the TP53 germline mutation.
The initial laboratory findings revealed pancytopenia; a white blood cell count of 1940/mL with 0.5% blasts, 11.1 g/dL hemoglobin, and a platelet count of 36,000/mL in the peripheral blood. The bone marrow (BM) examination showed infiltration of 17.1% blast cells with dysplasia in megakaryocytes and the presence of clusters of CD34-positive precursor cells, and also revealed hypoplastic and fibrous BM. An immunophenotypic analysis disclosed that the cells were positive for CD4, CD7, CD13, CD33, CD34, CD117, and HLA-DR. The patient was diagnosed with t-MDS (RAEB2). Twenty metaphase cells revealed a karyotype of 45,XY, t(3;21)(q26.2;q22), À 7 [8] , 46 idem, +8 [7] , 46,XY [5] . Fluorescence in situ hybridization (FISH) demonstrated monosomy 7 and trisomy 8, and an AML1/EVI1 gene translocation was detected by reverse transcription-PCR (RT-PCR).
Because of the cardiotoxicity of anthracyclines and hypoplastic marrow, AML-type induction chemotherapy was predicted to be poorly tolerated, so he started chemotherapy with low-dose cytarabine (AraC) alone; 7 doses of 50 mg/m 2 were administered ( Fig. 1) . However, he did not respond, so the AraC was changed to AZA. A second round of chemotherapy using 7 doses of 75 mg/m 2 was administered without complications. This treatment was not effective too, that is, trasfusion dependency was maintained and the BM examination showed infiltration of >80% monosomy 7 or trisomy 8 cells (FISH).
Therefore, the patient underwent allogeneic peripheral blood stem cell transplantation from a HLA-matched sibling at 2 months after the diagnosis without having achieved a CR. The conditioning regimen was busulfan; 3.2 mg/kg on days À7 to À 6, and fludarabine; 30 mg/m 2 on days À5 to À2, and melphalan; 70 mg/m 2 on days À 3 to À 2, and the graft versus host disease (GVHD) prophylaxis was performed using cyclosporine alone. Engraftment was achieved on day 10, and acute GVHD (skin grade II) was observed. A CR and complete donor chimerism were obtained in the BM, and monosomy 7 and trisomy 8 were no longer detected by FISH, but an AML1/EVI1 fusion transcript was detected by RT-PCR. Forty-one days after the peripheral blood stem cell transplantation, the patient was started on low-dose AZA subcutaneously; 5 doses of 32 mg/m 2 after withdrawal of cyclosporine, based on recent reports. 3, 4 After 3 cycles of low-dose AZA every 4 weeks, there was no hematological toxicity, and a CR had been maintained, but an AML1/EVI1 fusion transcript was still detected by RT-PCR. Therefore, the patient received a higher dose of AZA; 5 doses of 75 mg/m 2 every 4 weeks from the fourth to ninth cycles. Reversible grade1 neutropenia occurred, rather, platelets increased gradually.
After the ninth cycle of AZA, the AML1/EVI1 fusion transcript in the BM disappeared, and AZA was discontinued. During AZA treatment, there were no manifestations of GVHD. The patient is now doing well, and has been free from recurrence for over 26 months after the HSCT.
DISCUSSION
Therapy-related MDS/AML is a long-term complication of pediatric cancer. Although patients have benefitted from AML-type induction chemotherapy, followed by HSCT as postremission therapy, childhood t-MDS/AML has a poor prognosis. 6 Disruption of chromosome 3q26 is a rare but recurrent cytogenetic aberration that occurs in AML or MDS, and among several types of 3q26 aberrations, the most common are inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and t(3;21)(q26.2;q22). Shaoying and colleagues have reported clinicopathologic, cytogenetic, and survival data for 17 MDS/AML patients associated with t(3;21)(q26.2;q22) (12 patients had t-MDS, 4 patients had t-AML, and 1 patient had de novo AML). They described that MDS/AML associated with t(3;21)(q26.2;q22) usually showed marked multilineage dysplasia and frequent association with À 7 and a complex karyotype, furthermore, all 17 patients died with 1-and 2-year survival rates of 35% and 6%, respectively. 7 Chromosome 3q26.2 abnormalities have been shown to activate EVI1 expression. EVI1 plays an important role in pathogenesis by promoting myeloid proliferation and blocking differentiation. Vazquez et al 8 have confirmed that EVI1 overexpression is an adverse prognostic factor in AML patients and the total absence of EVI1 expression might have a prognostic impact on the outcome of AML patients, and that this pattern may be regulated by epigenetic mechanisms involving DNA methylation.
Previous clinical studies in patients with MDS and AML after allogeneic HSCT have shown that low doses of AZA (8 to 40 mg/m 2 /d for 5 d every 4 wk) as salvage or maintenance therapy could be a potential treatment option to prevent or delay hematological relapse. 4, 5 So we herein presented a case of pediatric t-MDS with À7/ + 8/ t(3;21)(q26.2;q22) that was treated with 9 cycles of AZA for minimal residual disease (MRD) (AML1/EVI1 fusion transcript) after allogeneic HSCT. The patient received 3 cycles of low-dose AZA (32 mg/m The hematological toxicity and infectious complications associated with AZA treatment were reversible and acceptable, and no other toxicities were recognized. The use of AZA was not associated with exacerbation of GVHD. After 9 cycles of AZA, AML1/EVI1 fusion transcript disappeared and AZA was discontinued. The patient has been free from recurrence for over 26 months after the HSCT and over 14 months after the discontinuance of AZA, although he did not achieve a CR before HSCT.
The German RELAZA trial evaluated the efficacy of AZA in the setting of MRD-triggered preemptive therapy to prevent or delay hematological relapse in patients with MDS or AML after allogeneic HSCT. After only 4 cycles of AZA (75 mg/m 2 /d for 7 d), the MRD was diminished or stabilized in 80% of patients (16 of 20 patients) in the absence of a hematological relapse. Nevertheless, for 65% of patients, a hematological relapse after the initial response could not be finally prevented; 13 patients eventually relapsed, but the time to relapse was considerably prolonged. 5 There is no previous data proven that the AML1/EVI1 gene translocation was eliminated by the AZA therapy. However EVI1 expression may be regulated by epigenetic mechanisms involving DNA methylation, 6 so the use of AZA may have been useful for the EVI1-induced leukemogenesis in this patient.
Furthermore, recent results suggest that AZA treatment of allotransplanted mice mitigates deleterious GVHD while preserving the beneficial graft-versus-leukemia effect, because AZA induces FOXP3 expression in naive T cells, which in turn induces the production of a regulatory T-cell population. 9, 10 Preemptive AZA treatment for MRD has an acceptable safety profile and appears to be an effective strategy in pediatric patients with high-risk MDS after HSCT. There are little data available about AZA therapy after HSCT in pediatric MDS/AML, and therefore, further studies are needed.
